Lispro

ApprovedSmall molecule

Eli Lilly

Lispro is one of 111 small molecule programs targeting Diabetic Nephropathy. It is currently in Approved.

Indications

Total Trials

Active Trials

110

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic NephropathyActive, not recruiting

Diabetes MellitusActive, not recruiting

Type 2 DiabetesActive, not recruiting

Type 1 DiabetesActive, not recruiting

Diabetic NephropathyApproved

Active, not recruiting

Diabetes MellitusPhase 3

Active, not recruiting

Type 2 DiabetesApproved

Active, not recruiting

Type 1 DiabetesPhase 3

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Lispro

Eli Lilly

Approved

3 2

Byetta

AstraZeneca

Preclinical

55 3

Jardiance

Boehringer Ingelheim

Preclinical

31 4

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 5

Sulfonylureas

Eli Lilly

Preclinical

1 6

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

2 7

GLP-1

RRigshospitalet, Denmark

Preclinical

1 8

Blank Control

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Preclinical

1 9

Antiplatelet Drug

FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Preclinical

1 10

Insulins

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 1 Diabetes5 trials

Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec

Active, not recruiting·DDiasome Pharmaceuticlas, Inc.·Phase 2·NCT06238778·227 enrolled

Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes

Withdrawn·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT00505882

Insulin Bolus Required for High Fat Foods in Type 1 Diabetes

Completed·JJoslin Diabetes Center·N/A·NCT02248454·10 enrolled

Show 2 more trials

Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents

Completed· Sanofi logo

Sanofi·Phase 3·NCT00046501·250 enrolled

Automated Fully Closed-Loop Insulin Delivery in Type 1 Diabetes With Ultra-Rapid Lispro (ACOLYTE Study)

Unknown status·MManchester University NHS Foundation Trust·N/A·NCT05660941·26 enrolled

Type 2 Diabetes3 trials

The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00279201·2,091 enrolled

A Study of Postprandial Hyperglycemia in Participants With Type 2 Diabetes

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT01159938·72 enrolled

Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes

Completed·EEmory University·Phase 4·NCT01378117·90 enrolled

Remission1 trial

Remission Through Early Monitored Insulin Therapy - Duration Month

Completed·SSandra Sobel·Phase 4·NCT03670641·10 enrolled

ART1 trial

A Study of Lispro Formulations in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02293551·54 enrolled

Diabetes Mellitus1 trial

Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus

Completed· Sanofi logo

Sanofi·Phase 3·NCT00467376·485 enrolled

5 more indications

Diabetic Nephropathy1 trial

Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy

Completed·NNanfang Hospital, Southern Medical University·Phase 4·NCT02690883·92 enrolled

Lip1 trial

SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)

Completed·—·Phase 4·NCT05579119·76 enrolled

MPA1 trial

A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro

Completed·BBiodel·Phase 2·NCT01000922·24 enrolled

Safety and Efficacy1 trial

A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)

Completed·BBiodel·Phase 2·NCT01686620·132 enrolled

Unspecified1 trial

To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy

Completed·BBiodel·Phase 3·NCT01110746·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Lispro. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lispro compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lispro. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Eli Lilly

Lispro

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 1 Diabetes5 trials

Type 2 Diabetes3 trials

Remission1 trial

ART1 trial

Diabetes Mellitus1 trial

Diabetic Nephropathy1 trial

Lip1 trial

MPA1 trial

Safety and Efficacy1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News